perphenazine and risperidone

perphenazine has been researched along with risperidone in 74 studies

Research

Studies (74)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (8.11)	18.2507
2000's	38 (51.35)	29.6817
2010's	26 (35.14)	24.3611
2020's	4 (5.41)	2.80

Authors

Authors	Studies
Choudhary, MS; Craigo, SC; Meltzer, HY; Monsma, FJ; Roth, BL; Shen, Y; Sibley, DR; Uluer, A	1
Topliss, JG; Yoshida, F	1
Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S	1
Glennon, RA	1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY	1
Herrick-Davis, K; Purohit, A; Smith, C; Teitler, M	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Lombardo, F; Obach, RS; Waters, NJ	1
Ahman, M; Holmén, AG; Wan, H	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Chen, Y; Liu, BF; Liu, S; Liu, X; Qiu, Y; Wang, S; Xu, X; Yu, M; Zhang, G; Zhang, T; Zhao, S	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Fensbo, C; Høyberg, OJ; Lingjaerde, O; Remvig, J; Salvesen, I; Sloth-Nielsen, M	1
Cesková, E; Svestka, J	1
DeMaso, DR; Steingard, RJ; Zimnitzky, BM	1
Canuso, CM; Green, AI; Hanau, M; Jhamb, KK	1
Branch, RA; Carter, CS; Coley, KC; DaPos, SV; Maxwell, R; Wilson, JW	1
DeMichele, MA; Henteleff, RA; Kirshner, MA; Meinert, KA; Pollock, BG; Sorisio, DA; Sweet, RA	1
Hong, X; Wang, X	1
Gil-ad, I; Shiloh, R; Shtaif, B; Weizman, A	1
Lieberman, JA; Stroup, TS	1
Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lebowitz, BD; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS	1
Andersen, TH; Bech, P; Larsen, NE	1
Delisi, LE; Nasrallah, HA	1
Luchins, DJ	1
Hsiao, JK; Lieberman, JA	1
Banks, SM; Pandiani, JA	1
Basu, D; Gupta, N	1
Ascher-Svanum, H; Faries, D; Landbloom, R; Swanson, J; Swartz, M; Zhu, B	1
Glick, ID; Schreiner, A; Shkedy, Z	1
Boshoven, W; Duncan, E; Dunlop, BW; Hamer, RM; Phillips, LS; Woolson, SL	1
Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS	1
Capuano, G; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; McGee, MF; Perkins, DO; Reimherr, F; Rosenheck, RA; Stroup, TS; Swartz, MS	1
Ganguli, R; Keshavan, M; Miewald, J; Strassnig, M	1
Bilder, RM; Capuano, G; Davis, CE; Davis, SM; Gold, JM; Green, MF; Harvey, PD; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Palmer, BW; Perkins, DO; Rosenheck, RA; Stroup, TS; Swartz, MS	1
Bick, P; Castle, D; Knoesen, N	1
Canive, JM; Davis, SM; Hsiao, JK; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Stroup, TS; Swanson, JW; Swartz, MS; Wagner, HR	1
Allingham, B; Citrome, L; Jaffe, A; Levine, J; Martello, D	1
Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Rosenheck, RA; Stroup, TS; Swartz, MS	1
Daumit, GL; Davis, SM; Davis, VG; Goff, DC; Hsiao, J; Lieberman, JA; McEvoy, JP; Meyer, JM; Nasrallah, HA; Stroup, TS; Swartz, MS	1
Fusar-Poli, RR	1
Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS	1
Ayesa, R; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pérez-Iglesias, R; Ramirez-Bonilla, M; Rodríguez-Sánchez, JM; Vázquez-Barquero, JL	1
Aberg, K; Adkins, DE; Lieberman, JA; McClay, JL; Perkins, DO; Stroup, S; Sullivan, PF; van den Oord, EJ; Vladimirov, VI	1
Cohen, D; Correll, CU; De Hert, M	1
Campbell, EC; Caroff, SN; Chakos, MH; Davis, SM; Davis, VG; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, DD; Riggio, S; Rosenheck, RA; Saltz, BL; Stroup, TS; Swartz, MS	1
Friis, S; Haahr, U; Johannessen, JO; Larsen, TK; McGlashan, TH; Melle, I; Opjordsmoen, S; Rund, BR; Simonsen, E; Vaglum, P	1
Dudova, I; Hrdlicka, M; Urbanek, T; Zedkova, I	1
Czernikiewicz, A; Kucharska-Pietura, K; Mortimer, A; Tylec, A	1
Chrisphonte, P; Ostroff, RB; Rosenheck, RA	1
Hermes, E; Rosenheck, R	1
Anand, R; Davidson, M; Geffen, Y; Keefe, R; Rabinowitz, J	1
Berle, JØ; Fasmer, OB; Løberg, EM	1
Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J	1
Fischer, BA	1
Lin, H; Rosenheck, R	1
Brennan, MD; Ramsey, TL	1
Lin, H; McEvoy, J; Mohamed, S; Rosenheck, RA; Stroup, S; Swartz, M	1
Alphs, L; Correll, CU; Kim, E; Mao, L; Starr, HL	1
Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T	1
Hoti, F; Lähteenvuo, M; Taipale, H; Tanskanen, A; Tiihonen, J; Vattulainen, P; Vieta, E	1
Bagheri, M; Barzegar, F; Charati, JY; Farnia, S; Hendouei, N; Hoseini, SD; Mohseni, F; Salehi, A; Shadfar, F; Shaki, F	1
Bellavia, A; Centorrino, F; Fitzmaurice, G; Jackson, JW; Valeri, L	1
Bareis, N; Stroup, TS	1
Correll, CU; DiPetrillo, L; Jiang, Y; Liu, Y; Pathak, S; Todtenkopf, MS	1
Dhindsa, RS; Goldstein, DB; Krizay, DK; Vasavda, C; Zoghbi, AW	1
Correll, CU; Leucht, S; Luykx, JJ; Solmi, M; Taipale, H; Tanskanen, A; Tiihonen, J	1
Chen, Q; Coid, J; Deng, W; Guo, W; Li, K; Li, L; Li, T; Lu, T; Lv, L; Ma, X; Tan, L; Tan, Q; Tao, S; Wang, C; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L	1

Reviews

3 review(s) available for perphenazine and risperidone

Article	Year
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). Journal of medicinal chemistry, 2003, Jul-03, Volume: 46, Issue:14 Topics: Animals; Humans; Ligands; Receptors, Serotonin; Serotonin Agents; Serotonin Antagonists; Serotonin Receptor Agonists	2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. The Cochrane database of systematic reviews, 2018, Jan-22, Volume: 1 Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disorders; Olanzapine; Patient Dropouts; Perphenazine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Substance-Related Disorders; Thiazoles	2018

Trials

29 trial(s) available for perphenazine and risperidone

Article	Year
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta psychiatrica Scandinavica, 1993, Volume: 88, Issue:6 Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Denmark; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Norway; Parkinson Disease, Secondary; Perphenazine; Piperidines; Prevalence; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index	1993
[Efficacy and tolerance of risperidone in various doses (report of a study)]. Ceska a slovenska psychiatrie, 1996, Volume: 92, Issue:1 Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Perphenazine; Risperidone; Schizophrenia	1996
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:12 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cholinergic Antagonists; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Female; Follow-Up Studies; Haloperidol; Hospital Costs; Hospitalization; Humans; Male; Mental Disorders; Middle Aged; Patient Readmission; Perphenazine; Psychotic Disorders; Retrospective Studies; Risperidone; Treatment Outcome	1999
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Method; Female; Humans; Lipids; Male; Olanzapine; Patient Compliance; Perphenazine; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain	2005
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss. Nordic journal of psychiatry, 2005, Volume: 59, Issue:3 Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Buspirone; Denmark; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Pilot Projects; Risperidone; Schizophrenia; Schizophrenic Psychology; Serotonin Receptor Agonists; Weight Loss	2005
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC psychiatry, 2006, Feb-21, Volume: 6 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bias; Clozapine; Drug Administration Schedule; Episode of Care; Female; Follow-Up Studies; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Perphenazine; Proportional Hazards Models; Research Design; Risperidone; Schizophrenia; Time Factors; Treatment Outcome; United States	2006
Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. International clinical psychopharmacology, 2006, Volume: 21, Issue:5 Topics: Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Haloperidol; Humans; Male; Perphenazine; Risperidone; Schizophrenia; Treatment Outcome	2006
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Olanzapine; Patient Dropouts; Perphenazine; Proportional Hazards Models; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Follow-Up Studies; Health Status; Humans; National Institute of Mental Health (U.S.); Olanzapine; Patient Dropouts; Perphenazine; Piperazines; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Thiazoles; Treatment Outcome; United States	2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of general psychiatry, 2007, Volume: 64, Issue:6 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Cohort Studies; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome	2007
Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2007, Volume: 15, Issue:6 Topics: Antipsychotic Agents; Australia; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; Humans; Olanzapine; Perphenazine; Piperazines; Psychiatry; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors	2007
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophrenia research, 2008, Volume: 100, Issue:1-3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Dibenzothiazepines; Double-Blind Method; Female; Humans; Illicit Drugs; Male; Olanzapine; Patient Dropouts; Perphenazine; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Substance-Related Disorders; Time Factors; Treatment Outcome; Treatment Refusal	2008
What CATIE found: results from the schizophrenia trial. Psychiatric services (Washington, D.C.), 2008, Volume: 59, Issue:5 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Psychology; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles	2008
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophrenia research, 2008, Volume: 103, Issue:1-3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Triglycerides	2008
Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia research, 2009, Volume: 107, Issue:1 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Female; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult	2009
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. The Journal of clinical psychiatry, 2009, Apr-21, Volume: 70, Issue:5 Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Prospective Studies; Psychotic Disorders; Risperidone; Severity of Illness Index; Sulpiride; Thiazoles	2009
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Molecular psychiatry, 2011, Volume: 16, Issue:1 Topics: Antipsychotic Agents; Benzodiazepines; Chromosomes, Human, Pair 4; Dibenzothiazepines; Double-Blind Method; Follow-Up Studies; Genome-Wide Association Study; Humans; Olanzapine; Perphenazine; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome	2011
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Movement Disorders; Olanzapine; Perphenazine; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome	2011
Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:9 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Olanzapine; Patient Acceptance of Health Care; Patient Dropouts; Patient Participation; Perphenazine; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sex Characteristics	2012
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:9 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dopamine Antagonists; Double-Blind Method; Female; GABA Agonists; gamma-Aminobutyric Acid; Humans; India; Male; Maximum Tolerated Dose; Middle Aged; Perphenazine; Risperidone; Romania; Schizophrenia; United States	2012
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS spectrums, 2014, Volume: 19, Issue:5 Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles	2014
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. The Journal of nervous and mental disease, 2014, Volume: 202, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Sample Size; Schizophrenia; Thiazoles; Treatment Outcome	2014
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial. Schizophrenia research, 2014, Volume: 160, Issue:1-3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers, Pharmacological; Dibenzothiazepines; Female; Genotyping Techniques; Glucagon-Like Peptide-1 Receptor; Haplotypes; Humans; Male; Models, Genetic; Olanzapine; Perphenazine; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Receptors, Glucagon; Regression Analysis; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain; White People	2014
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal of nervous and mental disease, 2015, Volume: 203, Issue:7 Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Cross-Sectional Studies; Dibenzothiazepines; Double-Blind Method; Female; Humans; Illicit Drugs; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Smoking; Smoking Prevention; Substance-Related Disorders; Thiazoles; Young Adult	2015
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. CNS spectrums, 2016, Volume: 21, Issue:6 Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Delayed-Action Preparations; Female; Haloperidol; Humans; Hyperprolactinemia; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Perphenazine; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome	2016
The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial. Schizophrenia research, 2019, Volume: 206 Topics: Adult; Antipsychotic Agents; Body-Weight Trajectory; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Weight Gain	2019
Examination of heterogeneity in treatment response to antipsychotic medications. Schizophrenia research, 2019, Volume: 211 Topics: Adult; Antipsychotic Agents; Deprescriptions; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Mental Status and Dementia Tests; Olanzapine; Perphenazine; Proportional Hazards Models; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2019
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study. The Journal of clinical psychiatry, 2020, 03-17, Volume: 81, Issue:2 Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Hospitalization; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Symptom Flare Up; Thiazoles; Time Factors	2020
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia. Current neuropharmacology, 2024, Volume: 22, Issue:1 Topics: Antipsychotic Agents; Benzodiazepines; Glucose; Haloperidol; Humans; Inflammation; Olanzapine; Perphenazine; Quetiapine Fumarate; Risperidone; Schizophrenia	2024

Other Studies

42 other study(ies) available for perphenazine and risperidone

Article	Year
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. The Journal of pharmacology and experimental therapeutics, 1994, Volume: 268, Issue:3 Topics: Animals; Antipsychotic Agents; Cell Line; Molecular Structure; Rats; Receptors, Serotonin	1994
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:3 Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain	2003
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5 Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution	2004
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs. Psychopharmacology, 2005, Volume: 179, Issue:2 Topics: Amino Acid Substitution; Antipsychotic Agents; Cell Line; Cyclic AMP; Humans; Mutagenesis, Site-Directed; Mutation; Radioligand Assay; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Transfection	2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6 Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nature chemical biology, 2009, Volume: 5, Issue:10 Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics. Journal of medicinal chemistry, 2013, Jun-13, Volume: 56, Issue:11 Topics: Animals; Antipsychotic Agents; Avoidance Learning; Biological Availability; Coumarins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; In Vitro Techniques; Isoxazoles; Lethal Dose 50; Mice; Motor Activity; Prolactin; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Dopamine D3; Structure-Activity Relationship; Weight Gain	2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Use of risperidone in psychotic disorder following ischemic brain damage. Journal of child and adolescent psychopharmacology, 1996,Spring, Volume: 6, Issue:1 Topics: Adult; Brain Ischemia; Haloperidol; Humans; Male; Perphenazine; Psychotic Disorders; Risperidone	1996
Olanzapine use in women with antipsychotic-induced hyperprolactinemia. The American journal of psychiatry, 1998, Volume: 155, Issue:10 Topics: Adult; Amenorrhea; Antipsychotic Agents; Benzodiazepines; Female; Galactorrhea; Humans; Hyperprolactinemia; Middle Aged; Olanzapine; Perphenazine; Pirenzepine; Risperidone; Schizophrenia	1998
Antipsychotic radioreceptor assay: a modification identifying selective receptor effects. Therapeutic drug monitoring, 2001, Volume: 23, Issue:4 Topics: Antipsychotic Agents; Cells, Cultured; Chromatography, High Pressure Liquid; Fibroblasts; Humans; Perphenazine; Radioligand Assay; Receptors, Dopamine D2; Receptors, Dopamine D4; Risperidone	2001
Agranulocytosis and neutropenia with typical and atypical neuroleptics. The American journal of psychiatry, 2001, Volume: 158, Issue:10 Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Leukocyte Count; Neutropenia; Olanzapine; Perphenazine; Pirenzepine; Risperidone; Schizophrenia	2001
Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms. Cellular and molecular neurobiology, 2001, Volume: 21, Issue:6 Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Cell Cycle; Cell Survival; Clozapine; DNA Fragmentation; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Iatrogenic Disease; Mice; Mice, Inbred ICR; Neurons; Neurotoxins; Perphenazine; Pregnancy; Risperidone; Tumor Cells, Cultured	2001
Schizophrenia, VI: Treatments. The American journal of psychiatry, 2003, Volume: 160, Issue:10 Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Perphenazine; Piperazines; Pirenzepine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome	2003
The CATIE schizophrenia effectiveness trial. Schizophrenia research, 2005, Dec-01, Volume: 80, Issue:1 Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Drug Administration Schedule; Drug Tolerance; Humans; Olanzapine; Perphenazine; Quetiapine Fumarate; Risperidone; Schizophrenia; Treatment Outcome	2005
Interpreting the results of the CATIE study. Psychiatric services (Washington, D.C.), 2006, Volume: 57, Issue:1 Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; National Institute of Mental Health (U.S.); Perphenazine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; United States	2006
Interpreting the results of the CATIE study. Psychiatric services (Washington, D.C.), 2006, Volume: 57, Issue:1 Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome	2006
Interpreting the results of the CATIE study. Psychiatric services (Washington, D.C.), 2006, Volume: 57, Issue:1 Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome	2006
Antipsychotic drugs and schizophrenia. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Developing Countries; Health Policy; Humans; Olanzapine; Perphenazine; Risperidone; Schizophrenia	2006
Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population. International clinical psychopharmacology, 2007, Volume: 22, Issue:1 Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Chlorpromazine; Cohort Studies; Female; Fluphenazine; Haloperidol; Hospitals, Veterans; Humans; Hyperglycemia; Incidence; Male; Middle Aged; Olanzapine; Perphenazine; Retrospective Studies; Risk Assessment; Risk Factors; Risperidone; Southeastern United States; Time Factors; Veterans	2007
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophrenia research, 2007, Volume: 93, Issue:1-3 Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Perphenazine; Psychiatric Status Rating Scales; Reference Values; Risperidone; Schizophrenia; Weight Gain	2007
Did CATIE influence antipsychotic use? Psychiatric services (Washington, D.C.), 2008, Volume: 59, Issue:5 Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Humans; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles	2008
Clinical experiences and clinical trials. CNS spectrums, 2008, Volume: 13, Issue:6 Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Olanzapine; Perphenazine; Piperazines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome	2008
Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophrenia research, 2010, Volume: 117, Issue:1 Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Female; Finland; Haloperidol; Humans; Male; Perphenazine; Quetiapine Fumarate; Risperidone; Schizophrenia; Suicide; Survival Rate	2010
Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. Early intervention in psychiatry, 2009, Volume: 3, Issue:1 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Clopenthixol; Clozapine; Female; Humans; Imidazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Olanzapine; Perphenazine; Psychotic Disorders; Risperidone; Statistics, Nonparametric; Time Factors; Young Adult	2009
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses. Neuro endocrinology letters, 2011, Volume: 32, Issue:5 Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medical Records; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome	2011
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs. Medical science monitor : international medical journal of experimental and clinical research, 2012, Volume: 18, Issue:1 Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Attention; Benzodiazepines; Dibenzothiazepines; Emotions; Fluphenazine; Haloperidol; Humans; Memory; Middle Aged; Olanzapine; Perazine; Perphenazine; Quetiapine Fumarate; Recognition, Psychology; Risperidone; Schizophrenia; Sulpiride	2012
Perphenazine suspension: a new, old treatment, side effects and continuous use. The Psychiatric quarterly, 2012, Volume: 83, Issue:3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Clinical Trials as Topic; Drug Compounding; Drug Delivery Systems; Female; Fluphenazine; Haloperidol; Hospitals, Psychiatric; Humans; Male; Movement Disorders; Olanzapine; Patient Discharge; Perphenazine; Risperidone; Suspensions; Treatment Outcome	2012
Does changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report. BMC research notes, 2013, May-06, Volume: 6 Topics: Actigraphy; Antipsychotic Agents; Brain; Brain Waves; Cognition; Drug Substitution; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Perphenazine; Predictive Value of Tests; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome	2013
Schizophrenia research: where are we? The Journal of nervous and mental disease, 2014, Volume: 202, Issue:1 Topics: Antipsychotic Agents; Cognitive Behavioral Therapy; Family; Humans; Medication Adherence; Nonverbal Communication; Patient Education as Topic; Perphenazine; Research; Risperidone; Schizophrenia; Schizophrenic Psychology; Specialization; Stress, Psychological	2014
Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. JAMA psychiatry, 2018, 04-01, Volume: 75, Issue:4 Topics: Administration, Oral; Adult; Bipolar Disorder; Cohort Studies; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studies; Gabapentin; Humans; Injections, Intramuscular; Lithium Carbonate; Male; Middle Aged; Patient Readmission; Perphenazine; Prospective Studies; Psychotropic Drugs; Quetiapine Fumarate; Risk; Risperidone; Treatment Outcome	2018
Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 103 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biomarkers; Clozapine; Humans; Middle Aged; Oxidative Stress; Perphenazine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Young Adult	2018
A Transcriptome-Based Drug Discovery Paradigm for Neurodevelopmental Disorders. Annals of neurology, 2021, Volume: 89, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Carbamazepine; Computer Simulation; Drug Discovery; Epirizole; Gene Expression Profiling; Gene Expression Regulation; Humans; Induced Pluripotent Stem Cells; MCF-7 Cells; Mice; Naloxone; Narcotic Antagonists; Neural Stem Cells; Neurodevelopmental Disorders; Neurons; PC-3 Cells; Perphenazine; Primary Cell Culture; Risperidone; RNA-Seq; Single-Cell Analysis; Transcriptome; Trazodone; Trimipramine	2021
Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. Schizophrenia bulletin, 2022, 06-21, Volume: 48, Issue:4 Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Olanzapine; Perphenazine; Recurrence; Risperidone; Schizophrenia; Secondary Prevention	2022